It is difficult to sustain existing treatments over the long term because they have several side effects, like myopathy (GLP-1 receptor agonists), pancreatitis (DPP-4 inhibitors), urinary tract infections and genital infections (SGLT-2), bladder cancer, angioedema (ACE inhibitors), etc.; further, these are not cost-effective, and GLP-1 receptor agonists are orally inactive. The gene discussed is GLP1R; the disease is urinary bladder cancer.